Fampyra, known generically as fampridine or 4-aminopyridine, is an oral medication approved to improve walking ability in adults with multiple sclerosis (MS) who experience walking disabilities. It functions as a potassium channel blocker, aiming to…
In the ongoing battle against antimicrobial resistance, Fetroja (cefiderocol) has emerged as a promising solution for treating complicated infections caused by multidrug-resistant Gram-negative bacteria. Developed by Shionogi & Co.,Ltd., this innovative siderophore cephalosporin antibiotic has…
Antizol, the brand name for fomepizole, is an essential antidote used in the treatment of ethylene glycol and methanol poisoning. These toxic alcohols are commonly found in antifreeze, solvents, and various household products. Without prompt…
In a significant advancement for multiple myeloma treatment, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Elrexfio™ (elranatamab-bcmm) on August 14, 2023. This bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, developed…
In 2025, Dupixent (dupilumab), developed by Sanofi and Regeneron, continues to solidify its position as a leading treatment for various inflammatory diseases. Recent FDA approvals and impressive sales figures underscore its growing significance in the…
Calcort, the trade name for deflazacort in the United Kingdom, has been a cornerstone in the management of Duchenne Muscular Dystrophy (DMD) for decades. As a glucocorticoid with anti-inflammatory and immunosuppressive properties, deflazacort offers therapeutic…
Cystadane® (betaine anhydrous for oral solution) has long been a cornerstone in the treatment of homocystinuria, a rare genetic disorder characterized by elevated levels of homocysteine in the blood and urine. Approved by the U.S.…
In 2025, Cinryze (C1 inhibitor [human]), a plasma-derived therapy developed by Shire (now part of Takeda Pharmaceuticals), continues to play a pivotal role in the management of hereditary angioedema (HAE). As the first FDA-approved treatment…
Xolremdi(mavorixafor) is an innovative pharmaceutical compound that has gained significant attention in the medical and biotech industries. As a potential game-changer in targeted therapies, Xolremdi is being studied for its unique mechanism of action and…
Ojemda(tovorafenib) is an innovative precision medicine designed to combat specific types of cancer by targeting genetic mutations. As a next-generation kinase inhibitor, it represents a significant advancement in oncology, offering hope for patients with limited…
Anktiva(nogapendekin alfa inbakicept-pmln) is a cutting-edge therapeutic agent that has garnered significant attention in the medical and biotech communities. Understanding Anktiva’s mechanisms, applications, and benefits is crucial for healthcare professionals, researchers, and others exploring new…
Zevtera® (ceftobiprole medocaril sodium) is a fifth-generation cephalosporin antibiotic developed by Basilea Pharmaceutica. Approved by the U.S. FDA in April 2024, Zevtera offers a potent treatment option against a range of serious bacterial infections, including…
